Does Vraylar Cause Blood Pressure Increases or Interact with Irbesartan?
Vraylar (cariprazine) causes minimal increases in blood pressure at therapeutic doses and has no documented pharmacokinetic or pharmacodynamic interactions with irbesartan.
Blood Pressure Effects of Vraylar
Based on FDA labeling data, cariprazine demonstrates dose-dependent but clinically modest effects on blood pressure 1:
In schizophrenia trials (6 weeks):
- At therapeutic doses (1.5-6 mg/day): Systolic BP increased by +0.6 to +1.3 mmHg; diastolic BP increased by +0.2 to +1.6 mmHg
- At supratherapeutic doses (9-12 mg/day, not recommended): Systolic BP increased by +2.1 mmHg; diastolic BP increased by +3.4 mmHg 1
In bipolar mania trials (3 weeks):
- At therapeutic doses (3-6 mg/day): Systolic BP increased by +0.8 mmHg; diastolic BP increased by +1.5 mmHg
- At supratherapeutic doses (9-12 mg/day): Systolic BP increased by +1.8 mmHg; diastolic BP increased by +1.9 mmHg 1
In bipolar depression and major depressive disorder trials:
- Blood pressure changes were negligible, ranging from -0.7 to +0.3 mmHg for both systolic and diastolic measurements 1
Real-world data corroborates these findings. A 2025 study of 612 patients treated with cariprazine showed estimated annual blood pressure trajectories of -2.38 mmHg/year for systolic BP and -0.57 mmHg/year for diastolic BP, suggesting no clinically meaningful increases and potentially slight decreases 2.
Drug Interaction Assessment
No interaction exists between cariprazine and irbesartan. The 2025 AHA/ACC hypertension guidelines extensively detail drug-drug interactions relevant to antihypertensive management, focusing on CYP3A4 interactions (verapamil, diltiazem) and P-glycoprotein interactions (digoxin, dabigatran) 3, 4. Neither cariprazine nor irbesartan appear in these interaction tables.
Mechanistically:
- Cariprazine is metabolized primarily via CYP3A4 and CYP2D6 but does not significantly inhibit or induce these pathways at therapeutic doses
- Irbesartan is an angiotensin II receptor blocker with minimal drug interaction potential, metabolized via glucuronidation and CYP2C9, with no significant effects on other drug metabolism 5, 6, 7
Clinical Implications
You can safely prescribe Vraylar to patients taking irbesartan without dose adjustments or additional monitoring beyond standard care. The blood pressure increases observed with cariprazine at therapeutic doses (1.5-6 mg/day) are minimal—typically 0.2-1.6 mmHg—and unlikely to compromise blood pressure control in patients adequately managed on irbesartan.
Important Caveats:
Orthostatic hypotension risk: While Vraylar doesn't significantly raise blood pressure, the FDA label warns about decreased blood pressure when rising from sitting/lying positions, which could theoretically be additive with irbesartan's BP-lowering effects 1. Monitor for lightheadedness, particularly during dose initiation.
Avoid supratherapeutic doses: The maximum recommended dose is 6 mg/day. Doses of 9-12 mg/day show larger BP increases (up to 3.4 mmHg diastolic) without additional efficacy 1.
Long-acting effects: Cariprazine has a long half-life; side effects may emerge weeks after initiation or dose increases, requiring extended monitoring 1.
Monitor blood pressure routinely: Check BP at baseline and periodically during treatment, as you would with any psychiatric medication in a patient with hypertension 3, 4.